The Viking Vesta offers a serene, Scandinavian-inspired cruise experience with understated luxury, educational activities and ...

Located in historic Union Station, The Depot is the perfect destination to host your next pregame event, reception or conference.

There's a security bot on the ground in the hall further south, so be sure to hack it to follow you. Move into the atrium room and follow the guide arrow to Lamb's quarantine chamber. As soon as you ...

WakeMed has been exploring a merger with Atrium Health for several years, and the prospect of greater competition in the Triangle — and the deep pockets of its proposed partner — was worth bypassing a ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The freestanding emergency ...

Charlotte, N.C.-based Atrium Health and Raleigh, N.C.-based WakeMed Health & Hospitals announced on May 1 plans to combine into a single health system, which the organizations said involves a $2 ...

The Wake County Board of Commissioners plans to vote Monday to alter WakeMed's articles of incorporation and a land deal between the county and hospital system to pave the way for a merger with ...

Atrium Health plans to take control of WakeMed in a deal that could bring at least $2 billion in new investment to Wake County, documents filed with Wake County indicate. It also lets Atrium grow its ...

The DoubleTree Suites by Hilton Chicago — Downers Grove recently unveiled a $2 million atrium. The hotel has constructed a fully enclosed, purpose-built ballroom within the existing multistory atrium.

Kathleen Gallagher is chief executive of Atrium, which is developing siRNA therapies for genetic cardiomyopathies. As Novartis completed its $12 billion takeover of Avidity, a new cardiology-focused ...

When Novartis agreed to buy RNA therapies developer Avidity Biosciences last fall, the companies said the plan was to spin out Avidity’s cardiology assets into a separate, publicly traded company.

A new biotech has taken flight as a result of Novartis’ red-hot $12 billion acquisition of muscular dystrophy specialist Avidity Biosciences. A spinout planned since that deal’s October announcement ...